Chest Medicine | Page 58 of 170 | Links Medicus Content Curation & Alerts in Medicine

Still in the midst of #SARSCoV2 #pandemic, still so much to learn… but #COVID19 experience should transform approach to research on RVIs
🦠antiviral therapy
🦠corticosteroids
🦠specific immune modulation
🦠anticoagulation
🦠respiratory support#COVIDFOAM https://t.co/WVKRSJARvl pic.twitter.com/qMkB4tkz06

— Intensive Care Medicine (@yourICM) August 11, 2021

M-A of randomized trials: proton pump inhibitors for gastro-esophageal reflux disease does not improve outcomes in patients with asthma.

13 Aug, 2021 | 08:53h | UTC

Randomised trials of proton pump inhibitors for gastro-oesophageal reflux disease in patients with asthma: an updated systematic review and meta-analysis – BMJ Open

RCT: third dose of Moderna mRNA vaccine increases immunity in transplant recipients.

12 Aug, 2021 | 09:56h | UTC

Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients – New England Journal of Medicine

Editorial: Third Time’s a Charm — Covid-19 Vaccine Hope for Solid-Organ Transplant Recipients

Study: Among kidney transplant recipients who did not respond after 2 doses, a third dose of an mRNA-1273 vaccine induced a serologic response in 49% of patients.

Case series: Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients.

[Preprint] 3rd AstraZeneca shot gives strong immunity.

Commentaries on Twitter

https://twitter.com/hildabast/status/1425576801850433537

The authors conclude that a third-dose booster of mRNA-1273 vaccine should be considered for transplant recipients. https://t.co/Q3gakSaNjd pic.twitter.com/CMN8f7cq29

— NEJM (@NEJM) August 11, 2021

RCT: Evaluation of Moderna mRNA vaccine in adolescents.

12 Aug, 2021 | 09:58h | UTC

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents – New England Journal of Medicine

Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

RCT: Pfizer-BioNTech Covid-19 vaccine shows 100% efficacy in adolescents – mainly transient mild-to-moderate reactogenicity was frequently observed, such as injection-site pain (in 79 to 86% of participants), fatigue (in 60 to 66%), and headache (in 55 to 65%).

Commentaries on Twitter

The mRNA-1273 vaccine was effective in preventing #COVID19 in 12-to-17-year-olds. Immune response was similar to young adults. https://t.co/aC3Dmjqe2T pic.twitter.com/9RxgHApW29

— NEJM (@NEJM) August 11, 2021

The @moderna_tx covid vaccine trial in 3,732 teens, placebo-controlled, published today @NEJM with both excellent safety profile and efficacy vs covid, and immune response as least as good as young adults https://t.co/PVmhjwgwsU pic.twitter.com/3uCmteaWNx

— Eric Topol (@EricTopol) August 11, 2021

Moderna may be superior to Pfizer against Delta variant — breakthrough odds rise with time.

12 Aug, 2021 | 09:54h | UTC

Moderna may be superior to Pfizer against delta variant — breakthrough odds rise with time – CNBC

Original Study 1 (preprint): Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence – medRxiv

Original Study 2 (preprint): Neutralizing antibody responses to SARS-CoV-2 variants in vaccinated Ontario long-term care home residents and workers – medRxiv

Study shows AstraZeneca and Pfizer vaccines are effective against Delta variant, but both doses are needed.

[Preprint] Pfizer vs. Moderna COVID-19 vaccine effectiveness against the Delta variant in Qatar – Effectiveness against symptomatic disease due to Delta was 53.5% for Pfizer and 84.8% for Moderna; effectiveness against severe disease due to Delta was 89.7% for Pfizer and 100.0% for Moderna.

12 Aug, 2021 | 09:53h | UTC

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar – medRxiv

Study shows AstraZeneca and Pfizer vaccines are effective against Delta variant, but both doses are needed.

Commentary on Twitter

New and important data on Delta breakthrough infections, large Qatar experience and follow-up of > 1.2 million vaccinees https://t.co/2ye1Kz9OPV
2-doses vaccine effectiveness vs infections
Pfizer 53.5%
Moderna 84.8%
Either 57.2%
(replicates gap of recent Mayo Clinic study) pic.twitter.com/ghWuWbYPLH

— Eric Topol (@EricTopol) August 11, 2021

WHO’s Solidarity clinical trial enters a new phase with three new candidate drugs.

12 Aug, 2021 | 09:02h | UTC

WHO’s Solidarity clinical trial enters a new phase with three new candidate drugs – World Health Organization

Commentary:

WHO-led Trial Will Test Malaria and Cancer Medicines Against COVID-19 – Health Policy Watch

A giant trial of COVID-19 treatments organized by the WHO is restarting. Here are the drugs it’s betting on.

WHO Solidarity trial to restart with focus on drugs that act on immune responses caused by Covid-19.

Commentary on Twitter (thread – click for more)

WHO’s #COVID19 Solidarity clinical trial enters a new phase – Solidarity PLUS – with three new candidate drugs:
-artesunate
-imatinib
-infliximab

👉 https://t.co/K6tk22NnFf

— World Health Organization (WHO) (@WHO) August 11, 2021

Video: Frequently Asked COVID-19 Vaccine Questions – August 2021 Update.

12 Aug, 2021 | 08:59h | UTC

Frequently Asked COVID-19 Vaccine Questions – August 2021 Update – JAMA

Clinical features of vaccine-induced immune thrombocytopenia and thrombosis.

12 Aug, 2021 | 09:05h | UTC

Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis – New England Journal of Medicine

Commentary: Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features – TCTMD

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (several articles and resources on the subject)

Commentary on Twitter

The phenotypes of VITT were defined in 220 patients presenting a 14-day median after the first ChAdOx1 nCoV-19 dose. Mortality was 22%. https://t.co/ir0yG5X0BP #COVID19 #IDTwitter pic.twitter.com/iAfxs0I1Ce

— NEJM (@NEJM) August 11, 2021

2021 guidelines for management of venous thromboembolism in Latin America.

12 Aug, 2021 | 08:56h | UTC

ASH, ABHH, ACHO, Grupo CAHT, Grupo  CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America – Blood Advances

M-A: Asymptomatic SARS-CoV-2 infection – “we estimate that the percentage of infections that never developed clinical symptoms, and thus were truly asymptomatic, was 35.1%”.

11 Aug, 2021 | 08:49h | UTC

Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis – Proceedings of the National Academy of Sciences

Commentary on Twitter

The best comprehensive review of the asymptomatic status with Covid, >350 studies, just out @PNASNews https://t.co/xyfgyGXANL
Overall: true, never had symptoms 35%; children 47%@Pratha_Sah @Alison_Galvani @MeaganCFitz @YaleSPH & colleagues
(wonder what the rate is w/ Delta) pic.twitter.com/9W6wbvQno6

— Eric Topol (@EricTopol) August 10, 2021

PRINCIPLE RCT: Inhaled budesonide improves time to recovery from COVID-19 in people at high risk of complications in the community.

11 Aug, 2021 | 08:52h | UTC

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial – The Lancet

Invited Commentary: The use of inhaled corticosteroids in early-stage COVID-19

M-A: More than 50 long-term effects of COVID-19.

11 Aug, 2021 | 08:47h | UTC

More than 50 long-term effects of COVID-19: a systematic review and meta-analysis – Scientific Reports

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Cohort study: Risk factors for long covid in previously hospitalized children.

Viewpoint: The road to addressing Long Covid.

Review: Long covid—mechanisms, risk factors, and management.

Review: Symptoms, complications and management of long COVID.

Long Covid: fatigue, post-exertional malaise, and cognitive dysfunction are the most common symptoms, according to an international survey.

Studies elucidate poorly understood long COVID.

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Long Covid: 39% of patients report persistent symptoms more than seven months after diagnosis of COVID-19 in an outpatient setting.

[Preprint] Long Covid: Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people.

Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms.

Long Covid: Half of young adults with COVID-19 have persistent symptoms 6 months after, study finds.

[Preprint] Long Covid: Third of people infected have long term symptoms.

Opinion | Causation or confounding: why controls are critical for characterizing long COVID – “Many of the self-reported symptoms, such as intermittent headaches or tiredness, are nonspecific and prevalent in the general population”.

Almost 25% of COVID-19 patients develop long-lasting symptoms, according to a new report.

Perspective | The four most urgent questions about long COVID.

Systematic review: Frequency, signs and symptoms, and criteria adopted for long COVID-19.

Report: 376,000 people in UK have had long Covid symptoms for at least a year.

Systematic review of 45 studies including 9751 participants, most of which were hospitalized, found 73% had at least 1 persistent symptom for weeks after Covid-19.

COVID Morbidity – The emerging burden of long COVID is significant, and needs to be considered when evaluating the risk vs. benefit of pandemic measures.

One year after hospital discharge due to SARS-CoV-2 Infection, the prevalence of long-term cough, chest pain, dyspnea, and fatigue was 2.5%, 6.5%, 23.3%, and 61.2%, respectively

Population-based cohort study: Non-hospitalized COVID-19 patients have low-risk of serious long-term effects, but visits to general practitioners and outpatient hospital visits are increased.

One third of patients hospitalized with COVID-19 have lung changes after a year

Long Covid: Largest post-acute COVID-19 study to date examined the health outcomes in more than 73,000 people who’d had COVID-19 and were not hospitalized

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

Perspective | They Tested Negative for Covid. Still, They Have Long Covid Symptoms.

Large study finds 1 in 3 Covid-19 survivors have subsequent mental health and neurological conditions

Cohort study: One in ten have long-term effects 8 months following mild COVID-19

Long Covid Implications for the workplace

Long Covid in the UK – More than a million affected in February, survey suggests

Covid-19: Middle aged women face greater risk of debilitating long term symptoms

Persistent neurologic symptoms and cognitive dysfunction in non‐hospitalized Covid‐19 “long haulers”

Opinion | We need to start thinking more critically — and speaking more cautiously — about long Covid

Review | Post-acute COVID-19 syndrome

Long Covid | Four-month clinical status of a cohort of patients after hospitalization for COVID-19

Perspective | Long Covid isn’t as unique as we thought

Attributes and predictors of long COVID

WHO Report: Preparing for Long COVID 2021

Long Covid: Sequelae in adults at 6 Months after COVID-19 infection

How many people get ‘long COVID’ – and who is most at risk?

Long Covid: Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge

Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline

Patients, clinicians seek answers to the mystery of ‘Long COVID’

Long Covid: 6-month consequences of COVID-19 in patients discharged from hospital

[Preprint] Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact

NICE Guideline: Managing the long-term effects of COVID-19

Commentary on Twitter

https://twitter.com/svillapol/status/1425032774793285648

CDC Report: COVID-19 morbidity and mortality far exceed the potential risks of rare side effects caused by vaccines.

11 Aug, 2021 | 08:45h | UTC

Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021 – CDC Morbidity and Mortality Weekly Report

Review: Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis.

11 Aug, 2021 | 08:44h | UTC

Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine–Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis: A Review – JAMA Cardiology

NICE COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis.

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know.

Commentary on Twitter

https://twitter.com/JohnGRizk/status/1425126093288353800

RCT: Triaging acute pulmonary embolism for home treatment by Hestia vs. simplified PESI criteria – the tools were similarly effective, and more than a third of patients were treated at home with a low incidence of complications.

11 Aug, 2021 | 08:27h | UTC

Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial – European Heart Journal

Commentary on Twitter

Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial #EHJ #PE #PERT https://t.co/gszusChSyU pic.twitter.com/NOyKYsVQHo

— EHJ Editor-in-Chief (@ehj_ed) August 10, 2021

[Preprint] Phase 1/2 RCT: A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac.

10 Aug, 2021 | 09:58h | UTC

A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial – medRxiv

Commentary on Twitter

https://twitter.com/hildabast/status/1424644994120372224

A WHO expert explains why she believes the rush for Covid-19 boosters is premature.

10 Aug, 2021 | 09:56h | UTC

A WHO expert explains why she believes the rush for Covid-19 boosters is premature – STAT

Commentary on Twitter

Must read interview on rich nations rushing into booster doses

Dr @Kate_L_OBrien by @HelenBranswell @statnews

"We really have huge inequity right now in just getting primary doses to people. Does a third dose need to be given?"https://t.co/pRhYwINuKf pic.twitter.com/YQS6Nj0Hyi

— Madhu Pai, MD, PhD (@paimadhu) August 9, 2021